Cover Image
Market Research Report

Myocardial Infarction - Pipeline Review, H1 2019

Published by Global Markets Direct Product code 229746
Published Content info 294 Pages
Delivery time: 1-2 business days
Price
Back to Top
Myocardial Infarction - Pipeline Review, H1 2019
Published: March 18, 2019 Content info: 294 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Infarction - Pipeline Review, H1 2019, provides an overview of the Myocardial Infarction (Cardiovascular) pipeline landscape.

Myocardial infarction is the irreversible necrosis of heart muscle secondary to prolonged ischemia. Symptoms include pain, fullness, and/or squeezing sensation of the chest, jaw pain, toothache, headache, shortness of breath, nausea, vomiting, and/or general epigastric discomfort, sweating, heartburn and/or indigestion, arm pain, upper back pain and general malaise (vague feeling of illness).

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocardial Infarction - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Myocardial Infarction (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Infarction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 15, 8, 53, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 3, 20 and 4 molecules, respectively.

Myocardial Infarction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Infarction (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Myocardial Infarction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myocardial Infarction (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myocardial Infarction (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Infarction (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myocardial Infarction (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myocardial Infarction (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11116IDB

Table of Contents

  • Introduction
  • Myocardial Infarction - Overview
  • Myocardial Infarction - Therapeutics Development
  • Myocardial Infarction - Therapeutics Assessment
  • Myocardial Infarction - Companies Involved in Therapeutics Development
  • Myocardial Infarction - Drug Profiles
  • Myocardial Infarction - Dormant Projects
  • Myocardial Infarction - Discontinued Products
  • Myocardial Infarction - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Myocardial Infarction, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Myocardial Infarction - Pipeline by Actinogen Medical Ltd, H1 2019
  • Myocardial Infarction - Pipeline by Angion Biomedica Corp, H1 2019
  • Myocardial Infarction - Pipeline by Applied Therapeutics Inc, H1 2019
  • Myocardial Infarction - Pipeline by Athera Biotechnologies AB, H1 2019
  • Myocardial Infarction - Pipeline by Athersys Inc, H1 2019
  • Myocardial Infarction - Pipeline by Bharat Biotech Ltd, H1 2019
  • Myocardial Infarction - Pipeline by BioCardia Inc, H1 2019
  • Myocardial Infarction - Pipeline by Biscayne Pharmaceuticals Inc, H1 2019
  • Myocardial Infarction - Pipeline by Cadila Healthcare Ltd, H1 2019
  • Myocardial Infarction - Pipeline by Cardiol Therapeutics Inc, H1 2019
  • Myocardial Infarction - Pipeline by Celixir Ltd, H1 2019
  • Myocardial Infarction - Pipeline by CellProthera SAS, H1 2019
  • Myocardial Infarction - Pipeline by CFM Pharma Holding BV, H1 2019
  • Myocardial Infarction - Pipeline by Cynata Therapeutics Ltd, H1 2019
  • Myocardial Infarction - Pipeline by Diffusion Pharmaceuticals Inc, H1 2019
  • Myocardial Infarction - Pipeline by Evotec AG, H1 2019
  • Myocardial Infarction - Pipeline by EyeGene Inc, H1 2019
  • Myocardial Infarction - Pipeline by Faraday Pharmaceuticals Inc, H1 2019
  • Myocardial Infarction - Pipeline by Hemostemix Inc, H1 2019
  • Myocardial Infarction - Pipeline by HUYA Bioscience International LLC, H1 2019
  • Myocardial Infarction - Pipeline by Idorsia Pharmaceutical Ltd, H1 2019
  • Myocardial Infarction - Pipeline by InCarda Therapeutics Inc, H1 2019
  • Myocardial Infarction - Pipeline by Inotrem SA, H1 2019
  • Myocardial Infarction - Pipeline by K-Stemcell Co Ltd, H1 2019
  • Myocardial Infarction - Pipeline by Laboratoires Pierre Fabre SA, H1 2019
  • Myocardial Infarction - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2019
  • Myocardial Infarction - Pipeline by LG Chem Ltd, H1 2019
  • Myocardial Infarction - Pipeline by Lonestar Heart Inc, H1 2019
  • Myocardial Infarction - Pipeline by Mesoblast Ltd, H1 2019
  • Myocardial Infarction - Pipeline by MimeTech Srl, H1 2019
  • Myocardial Infarction - Pipeline by New World Laboratories Inc, H1 2019
  • Myocardial Infarction - Pipeline by Novartis AG, H1 2019
  • Myocardial Infarction - Pipeline by NuvOx Pharma LLC, H1 2019
  • Myocardial Infarction - Pipeline by OMEICOS Therapeutics GmbH, H1 2019
  • Myocardial Infarction - Pipeline by Opsona Therapeutics Ltd, H1 2019
  • Myocardial Infarction - Pipeline by Otsuka Holdings Co Ltd, H1 2019
  • Myocardial Infarction - Pipeline by Quark Pharmaceuticals Inc, H1 2019
  • Myocardial Infarction - Pipeline by Reata Pharmaceuticals Inc, H1 2019
  • Myocardial Infarction - Pipeline by Recardio GmbH, H1 2019
  • Myocardial Infarction - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2019
  • Myocardial Infarction - Pipeline by Rubicon Biotechnology Inc, H1 2019
  • Myocardial Infarction - Pipeline by Silver Creek Pharmaceuticals Inc, H1 2019
  • Myocardial Infarction - Pipeline by TaiGen Biotechnology Co Ltd, H1 2019
  • Myocardial Infarction - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019
  • Myocardial Infarction - Pipeline by Thrombolytic Science International LLC, H1 2019
  • Myocardial Infarction - Pipeline by Vicore Pharma AB, H1 2019
  • Myocardial Infarction - Pipeline by ViroMed Co Ltd, H1 2019
  • Myocardial Infarction - Pipeline by XBiotech Inc, H1 2019
  • Myocardial Infarction - Pipeline by YiChang Humanwell Pharmaceutical Co Ltd, H1 2019
  • Myocardial Infarction - Pipeline by Yuyu Pharma Inc, H1 2019
  • Myocardial Infarction - Dormant Projects, H1 2019
  • Myocardial Infarction - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Myocardial Infarction, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Top 10 Routes of Administration, H1 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2019
  • Number of Products by Top 10 Molecule Types, H1 2019
  • Number of Products by Stage and Top 10 Molecule Types, H1 2019
Back to Top